Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease

GÜL SEMA YILDIRAN KESKİN
ÖZANT HELVACI
ÇAĞRI YAYLA
ÖZGE TUĞÇE PAŞAOĞLU
ÇAĞLAR KESKİN

See next page for additional authors
Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease

Authors
GÜL SEMA YILDIRAN KESKİN, ÖZANT HELVACI, ÇAĞRI YAYLA, ÖZGE TUĞÇE PAŞAOĞLU, ÇAĞLAR KESKİN, SELİM TURGAY ARINSOY, and ÜLVER DERİCİ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol49/iss1/21
Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease

Gül Sema KESKİN¹, Özant HELVACI²*, Çağrı YAYLA³, Öze T. PAŞAOĞLU⁴, Çağlar KESKİN⁵, Turgay ARINSOY⁶, Ülver B. DERİCİ⁷

¹Department of Oncology, Faculty of Medicine, Başkent University, Ankara, Turkey
²Department of Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey
³Department of Cardiology, Yüksek İhtisas Hospital, Ankara, Turkey
⁴Department of Biochemistry, Faculty of Science, Gazi University, Ankara, Turkey
⁵Department of Endocrinology, Faculty of Medicine, Ankara University, Ankara, Turkey

* Correspondence: drozant@hotmail.com

1. Introduction
Chronic kidney disease (CKD) is an epidemic that affects 10%–15% of the modern world [1]. Numerous observational studies have demonstrated increased cardiovascular risk in the setting of CKD. Nearly half of the patients requiring renal replacement treatment die from cardiovascular diseases. Furthermore, age-adjusted cardiovascular mortality is 15–30 times higher in CKD patients than healthy subjects [1,2]. Traditional cardiovascular risk factors cannot clarify this significant difference. Therefore, nontraditional risk factors such as endothelial dysfunction, oxidative stress, and insulin resistance are being investigated. Endothelial dysfunction (ED) is related to cardiovascular disease and progression of CKD and it can be a causative factor for accelerated atherosclerosis in CKD patients [3,4]. ED was previously described as inadequate vasodilatation to certain stimuli. However, nowadays, we use a broader definition that includes proinflammatory and prothrombotic features of ED as well [5]. The degree of ED can be measured directly or indirectly.

YKL-40 is a novel biomarker for acute and chronic inflammation. It is also known as human cartilage glycoprotein 39 or chitinase-3-like protein 1 (CHI3L1). It is released from vascular smooth muscle cells, synovial cells, articular chondrocytes, activated neutrophils, cancer cells, and macrophages. A major source of circulating YKL-40 is mature macrophages. The primary functions of YKL-40 remain mostly unknown, but it is currently thought that YKL-40 may have a role in the proliferation of chondrocytes and fibroblasts, differentiation of macrophages, migration and reorganization of vascular endothelial cells, remodeling of the extracellular matrix, and inflammation [6–8]. Activated macrophages obtained from early atherosclerotic lesions have been shown to express very high levels of YKL-40 [9]. High serum levels of YKL-40 are associated with cardiovascular disease and mortality [10,11]. Serum YKL-40 levels are also increased in patients with diabetes mellitus and hypertension [12]. Another study from our department revealed peritoneal dialysis and hemodialysis (HD) patients had elevated levels of YKL-40 compared to healthy subjects [13].

Background/aim: We aimed to evaluate the relationship between YKL-40 and endothelial dysfunction in chronic kidney disease.

Materials and methods: Twenty-nine hemodialysis patients, 101 patients with nondialytic (stage 2, 3, 4, and 5 ND) chronic kidney disease (CKD), and 38 healthy individuals as a control group were included. YKL-40 levels were measured by ELISA. Endothelial dysfunction was indirectly measured by flow-mediated dilatation percentage (FMD) in the brachial artery.

Results: YKL-40 levels were higher in CKD patients than controls and highest in HD patients (P = 0.001). FMD values were lower in nondialytic CKD patients and lowest in HD patients (P = 0.001). YKL-40 negatively correlated with eGFR and FMD values (r = –0.674 and r = –0.471, respectively).

Conclusion: This study shows that YKL-40 increases with CKD stage and is negatively correlated with FMD measurements.

Key words: YKL-40, CKD, hemodialysis, atherosclerosis, endothelial dysfunction

Received: 27.04.2018  •  Accepted/Published Online: 08.12.2018  •  Final Version: 11.02.2019
In this cross-sectional study, we aimed to demonstrate the relationship between YKL-40 and ED in patients with CKD (2–5) (nondialytic CKD, stages 2–5) and CKD_{5D} (hemodialysis) patients.

2. Materials and methods

2.1. Patients

A cohort of 29 hemodialysis patients, 101 patients with nondialytic CKD (stages 2, 3, 4, and 5), and 38 healthy subjects were recruited between September 2012 and April 2013. All HD patients had a dialysis vintage of at least 3 months and all of them were on a three times weekly hemodialysis program for 4 h with standard bicarbonate dialysate and with synthetic membranes. CKD staging was done using the MDRD formula. The term “CKD (2–5) patient” was used to define patients with stage 2, 3, 4, and 5 (nondialysis) chronic kidney disease. For the control group, healthy subjects with no known diabetes, hypertension (excluded by two office measurements), cardiovascular disease, rheumatologic disease, or proteinuria (>200 mg/day) were selected. The local ethics committee of Gazi University, by the Declaration of Helsinki, approved the study (No: B.30.2.GUN.0.20/5847 - 14/9/2012); all participants gave their written informed consent before inclusion. Patient selection is presented in Figure 1.

Exclusion criteria for hemodialysis and CKD patients were as follows:

a) Age <18 or age >75
b) Active infection
c) Pregnancy
d) Malignancy
e) Active or prior history of SLE, rheumatoid arthritis
f) Coronary intervention (angiography, ballooning, stenting, coronary artery bypass graft) in the last 6 months

Demographic and clinical data such as diabetes, hypertension, hyperlipidemia, cardiovascular disease, and smoking status were recorded. Antihypertensives were recorded as alpha blockers, beta blockers, diuretics, ACE in/ARBs, and calcium channel blockers. Statins, ezetimibe, and fibrates were all recorded as lipid-lowering treatments. All patients had a routine physical examination performed by the same physician. Body mass index (BMI) was calculated as weight in kilograms divided by height per square meter.

2.2. Biochemical measurements

Routine blood count, fasting glucose, BUN, creatinine, uric acid, albumin, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, triglyceride, total cholesterol, C-reactive protein (CRP), and YKL-40 levels were measured in the department of biochemistry and hematology with automated procedures. eGFR was calculated by the MDRD formula. All blood samples were centrifuged immediately at 3000 rpm for 5 min and stored at ~20 °C until YKL-40 and CRP analysis. For YKL-40 levels, a commercially available ELISA kit (Cusabio Biotech., Wuhan, China) was used. Results are given as ng/mL. CRP was measured by the nephelometric method. All samples were obtained after at least 8 h of fasting. HD patients’ blood samples were collected before dialysis.

2.3. Assessment of endothelial function by flow-mediated dilatation
Flow-mediated dilatation (FMD) measurements were done on the dominant arm of healthy subjects and patients without arteriovenous fistulae. For the rest, measurements were done on the arm without the fistula. All measurements were done by the same physician, in the same place, and at room temperature. VIVID 7 (Vingmed-General Electric, Horten, Norway) ultrasonography was used for brachial artery sonography. At least 6 h of fasting, at least 12 h of abstinence from alcohol and caffeine, and 2 h of abstinence from nicotine was mandatory before measurements. End-diastolic brachial artery diameter (EBAD) was measured with the help of continuous electrocardiography monitoring. The mean of three consecutive measurements was accepted as the EBAD. At the same time, flow velocity was recorded. After this, the cuff was inflated to 50 mmHg higher than patients’ systolic blood pressure and was held for 5 min before being suddenly deflated. EBAD and flow velocity were rerecorded after 45 s (hyperemic response). FMD in response to reactive hyperemia was calculated as follows:

\[ \text{FMD (\%)} = \frac{\text{after hyperemia EBAD} - \text{basal EBAD}}{\text{basal EBAD}} \times 100 \]

2.4. Statistical analysis
Continuous variables were expressed as mean and standard deviations (SD) and categorical variables as frequency and percentage. Normal distribution patterns were tested with the Kolmogorov–Smirnov test. Independent samples t-test, the Mann–Whitney U test, and one-way analysis of variance (ANOVA) were used to test differences between groups when appropriate. Categorical variables were compared with the \( \chi^2 \) test. Correlation analyses between continuous variables were performed using univariate Spearman correlation analysis. \( P < 0.05 \) was considered statistically significant. All statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA).

3. Results
Groups were similar regarding age, sex, and smoking status \( (P > 0.05) \). Diabetes, hypertension, cardiovascular disease prevalence, and smoker frequency were identical between nondialytic CKD and HD patients \( (P > 0.05) \). Hyperlipidemia, BMI, hypertension, and mean blood pressure were different between each group. The difference was statistically significant. Demographic features of the cohort are given in Table 1.

| Variables                       | Control | CKD | HD      | P-value |
|---------------------------------|---------|-----|---------|---------|
| Age (mean ± SD)                 | 49.39 ± 11.7 | 53.10 ± 11.50 | 48.14 ± 14.52 | 0.053   |
| Sex (female)                    | 19 (50%) | 47 (46.5%) | 10 (34.5%) | 0.413   |
| BMI (kg/m²)                     | 26.69 ± 3.67 | 28.90 ± 4.75 | 24.57 ± 4.50 | <0.001  |
| CVD (present)                   | -       | 18 (17.8%) | 3 (10.3%) | 0.406   |
| Diabetes (present)              | -       | 42 (41.6%) | 7 (24.1%) | 0.136   |
| Hypertension (present)          | -       | 88 (87.1%) | 21 (72.4%) | 0.083   |
| Hyperlipidemia (present)        | 14 (38.9%) | 73 (72.3%) | 18 (62.1%) | 0.002   |
| Smoking (active smoker)         | 4 (10.5%) | 16 (16.2%) | 8 (27.6%) | 0.174   |

CVD: Cardiovascular disease, BP: blood pressure, HDL: high-density lipoprotein, CRP: C-reactive protein, FMD: flow-mediated dilatation, CKD: chronic kidney disease (stages 2–5, nondialysis), HD: hemodialysis.
CRP levels. However, nondialytic CKD patients had elevated diastolic and mean blood pressures compared to HD patients. Hemoglobin, albumin, HDL, LDL, total cholesterol, and FMD (%) were significantly lower in HD patients than nondialytic CKD patients. No difference between triglycerides was observed. YKL-40 levels were significantly higher in HD patients. Results are shown in Table 3.

### 3.1. Correlation analysis

YKL-40 and FMD did not correlate with BMI. YKL-40 had a negative correlation with FMD in multivariate analysis. Furthermore, YKL-40 was negatively associated with hemoglobin, albumin, and HDL and positively correlated with uric acid and CRP. FMD was in positive correlation with hemoglobin, albumin, and HDL while it negatively correlated with creatinine and uric acid. The

#### Table 2. Comparison of study parameters (control group vs. CKD+HD).

| Variables          | Control          | CKD+HD            | P-value |
|--------------------|------------------|-------------------|---------|
| BP (mean ± SD)     |                  |                   |         |
| Systolic           | 118.94 ± 10.6    | 129.68 ± 19.50    | 0.000   |
| Diastolic          | 72.76 ± 7.50     | 77.64 ± 12.56     | 0.024   |
| Mean               | 88.15 ± 7.67     | 94.99 ± 13.95     | 0.002   |
| Hemoglobin (g/dL)  | 14.00 ± 1.24     | 12.92 ± 2.06      | 0.002   |
| Albumin (g/dL)     | 4.30 ± 0.22      | 4.1 ± 0.48        | 0.001   |
| HDL (mg/dL)        | 48.54 ± 9.42     | 42.1 ± 11.05      | 0.001   |
| CRP (mg/L)         | 3.18 ± 2.39      | 9.07 ± 16.00      | 0.026   |
| Glucose (mg/dL)    | 90 ± 9           | 115 ± 51          | 0.000   |
| Uric acid (mg/dL)  | 5.13 ± 1.23      | 6.55 ± 1.64       | 0.000   |
| FMD (%)            | 13.24 ± 6.34     | 4.46 ± 3.65       | 0.000   |
| YKL-40 (ng/mL)     | 31.73 ± 21.12    | 61.68 ± 24.72     | 0.000   |

BP: Blood pressure, HDL: high-density lipoprotein, CRP: C-reactive protein, FMD: flow-mediated dilatation, CKD: chronic kidney disease (stages 2–5, nondialysis), HD: hemodialysis.

#### Table 3. Comparison of study parameters (CKD vs. HD).

| Variables          | CKD          | HD            | P-value |
|--------------------|--------------|---------------|---------|
| BP (mean ± SD)     |              |               |         |
| - Systolic         | 131.11 ± 17.97 | 124.14 ± 24.13 | 0.086   |
| - Diastolic        | 79.38 ± 11.94 | 70.86 ± 12.82 | 0.001   |
| - Mean             | 96.62 ± 13.04 | 88.62 ± 15.72 | 0.005   |
| Hemoglobin (g/dL)  | 13.40 ± 1.94  | 11.05 ± 1.36  | .000    |
| Albumin (g/dL)     | 4.17 ± 0.51   | 3.83 ± 0.42   | 0.041   |
| HDL (mg/dL)        | 42.89 ± 11.10 | 36.29 ± 9.26  | 0.003   |
| CRP (mg/L)         | 7.50 ± 9.54   | 14.66 ± 28.78 | 0.33    |
| Glucose (mg/dL)    | 118 ± 54      | 103 ± 37      | 0.08    |
| Uric acid (mg/dL)  | 6.64 ± 1.75   | 6.17 ± 1.04   | 0.067   |
| Proteinuria (mg/day)| 1598 ± 2458  | N/A           | N/A     |
| FMD (%)            | 4.85 ± 3.76   | 2.95 ± 2.78   | 0.014   |
| YKL-40 (ng/mL)     | 55.76 ± 23.09 | 83.92 ± 16.88 | 0.000   |

BP: Blood pressure, HDL: high-density lipoprotein, CRP: C-reactive protein, FMD: flow-mediated dilatation, CKD: chronic kidney disease (stages 2–5, nondialysis), HD: hemodialysis, N/A: not available.
analysis is summarized in Table 4. Subgroup analysis after HD patients were excluded revealed a positive association between creatinine and YKL-40 and a negative association between creatinine and FMD. As expected, the associations were vice versa for eGFR (MDRD). Box plots of FMD vs. YKL-40 and eGFR vs. YKL-40 are given in Figures 2 and 3. YKL-40 had a weak but positive correlation with proteinuria when nondialytic CKD patients were analyzed (Figure 4).

4. Discussion

In the present study, we explored the potential role of YKL-40 measurement in chronic kidney disease and dialysis patients. Our study indicates that YKL-40 levels were increased in patients with chronic kidney disease, especially hemodialysis patients. Elevated YKL-40 associated positively with CRP, creatinine, and uric acid and negatively with FMD, albumin, and hemoglobin. Importantly, our findings revealed that levels of YKL-40

| Variables                  | YKL-40 |       | FMD |
|----------------------------|--------|-------|-----|
|                            | r      | P     | r   | P   |
| Age                        | 0.174  | 0.024 | -0.045 | 0.575 |
| Body mass index            | -0.038 | 0.623 | -0.023 | 0.771 |
| Hemoglobin (g/dL)          | -0.478 | <0.001 | 0.291 | <0.001 |
| Albumin (g/dL)             | -0.429 | <0.001 | 0.266 | <0.001 |
| Creatinine (mg/dL)         | 0.610  | <0.001 | -0.592 | <0.001 |
| eGFR (MDRD)                | -0.674 | <0.001 | 0.597 | <0.001 |
| HDL (mg/dL)                | -0.366 | <0.001 | 0.180 | 0.027 |
| CRP (mg/L)                 | 0.358  | <0.001 | -0.170 | 0.038 |
| Glucose (mg/dL)            | 0.032  | 0.669 | -0.249 | 0.661 |
| Uric acid (mg/dL)          | 0.220  | 0.004 | -0.237 | 0.002 |
| YKL-40 (ng/mL)             | -      |      | -0.471 | <0.001 |
| FMD (%)                    | -0.471 | <0.001 |      |     |

BP: Blood pressure, HDL: High-density lipoprotein, CRP: C-reactive protein, FMD: flow-mediated dilatation.

![Figure 2. Correlation between FMD% and YKL-40 (P < 0.001, r: -0.471).](image-url)
correlated with eGFR. This finding also suggests that a potential mechanism for increased YKL-40 levels may be associated with reduced kidney functions.

Cardiovascular diseases are the most common reason for death in hemodialysis patients [1]. In this study, we aimed to investigate the relationship between YKL-40 and FMD, an indirect test of endothelial dysfunction. We revealed high levels of circulating YKL-40 in both nondialytic CKD and HD patients. Furthermore, we have shown that as eGFR decreases YKL-40 increases. Our results are in concordance with the literature. Studies on CKD, HD, peritoneal dialysis, and renal transplant patients have all shown a negative association between YKL-40 and eGFR [13–15].

Figure 3. Correlation between eGFR and YKL-40 (P < 0.001, r: –0.674).

Figure 4. Correlation between proteinuria and YKL-40 (P < 0.013, r: 0.254).
Primary cells secreting YKL-40 are macrophages and essential for acute and chronic inflammation. Thus, YKL-40 is readily accepted as an acute phase protein [16–18]. Our study reveals YKL-40's positive association with uric acid and CRP and negative association with albumin. This association may reflect the role of inflammation in the process of endothelial dysfunction in CKD and HD patients.

Measuring FMD by ultrasonography is a noninvasive, safe, and reproducible method to detect endothelial dysfunction and consequently to investigate preclinical atherosclerosis. Individuals, and especially patients with CKD, who have impaired endothelial function have a higher risk of CVD. It has been suggested that endothelial dysfunction facilitates the development of CVD in uremic patients. FMD decreases with age and has been shown to decrease in cases of CKD [17]. In our study patients, FMD measurements have been found lower in CKD and lowest in HD patients when compared to healthy subjects. A strong positive correlation with eGFR has also been observed. This observation makes us believe that endothelial dysfunction and inflammation go hand in hand for CKD and HD patients. Another support for our belief is uric acid and its correlations. Uric acid is a known oxidant and depletes endothelial nitric oxide [19]. Its inflammatory properties are well appreciated [20]. Kanbay et al. demonstrated that uric acid negatively correlates with FMD in a cohort of 263 nondiabetic, newly diagnosed nondiabetic CKD patients [21].

Lee et al. showed that YKL-40 increases in early diabetic nephropathy and it is an independent risk factor for albuminuria. They found that fractionated excretion of YKL-40 is low in both healthy controls and diabetic patients who have estimated glomerular filtration of more than ≥60 ml/min/1.73 m². They were also able to prove that urinary YKL-40 levels were elevated only in patients with macroalbuminuria [22]. It is unknown whether the high levels of urinary YKL-40 in macroalbuminuric patients is from reduced tubular reabsorption of YKL-40 or increased renal production of YKL-40 due to localized inflammation. Our results demonstrate that even when HD patients are not taken into consideration YKL-40 levels in patients with nondiabetic CKD increase with declining eGFR. Subgroup analysis of nondiabetic CKD patients proved a significant but weak correlation of YKL-40 with proteinuria. YKL-40 is a low molecular weight protein that is entirely filtered in the glomerular filtrate and then reabsorbed and catabolized in the proximal tubules [23]. We have no knowledge about the glomerular filtration and reabsorption rates of YKL-40 in nondiabetic chronic kidney disease. In these situations, not only are inflammation and endothelial dysfunction prominent, but the urinary excretion and catabolism rate of YKL-40 may also be decreased. We may postulate that decreased tubular reabsorption or increased local/systemic production via inflammatory pathways or both are responsible for elevated YKL-40 levels in patients with significantly reduced eGFR. We believe both mechanisms are involved since numerous studies have shown that YKL-40 is related to metabolic syndrome and its components (hypertension, hyperlipidemia, cardiovascular and cerebrovascular diseases), various cancers, obstructive sleep apnea syndrome, chronic allograft nephropathy, and Alzheimer disease [15,24–27]. In these studies, patients with normal kidney function had elevated YKL-40 levels. That also proves that there is a threshold for tubular reabsorption and it can be exceeded with overproduction.

Our study has several strengths. It compares patients with different degrees of renal dysfunction with healthy controls and proves that as renal dysfunction progresses YKL-40 and endothelial dysfunction also increase. There is a limited English literature about YKL-40 and hemodialysis. Our study is the first to establish the relation between YKL-40 and endothelial dysfunction in HD patients. However, there are also limitations that should be mentioned. First, this is a sectional study. Therefore, no assumptions can be made about future clinical implications of endothelial dysfunction. Second, the number of HD patients is low compared to control and nondialytic CKD patients. That may have interfered with the statistics. Third, YKL-40 was only measured once, and serial measurements and their means could provide more reliable data for certain individuals. Last, due to the nature of FMD measurements, some patients with poor performance status did not volunteer for the study, which may have created a selection bias. That bias is particularly important since patients who did not wish to participate tended to have multiple comorbidities and their YKL-40 levels could have been higher than in our HD patient cohort. Had they been included, more striking differences between HD patients and other groups could have been observed.

In conclusion, YKL-40 is a new inflammatory marker that is elevated in patients with various stages of kidney disease. This study shows that YKL-40 increases with CKD stage; is negatively correlated with FMD measurements, hemoglobin, HDL, and albumin and is positively correlated with CRP and uric acid levels. We believe that YKL-40 is a significant marker to assess both endothelial dysfunction and inflammatory processes in CKD. We think that after sufficient data are obtained anti-YKL-40 antibodies may offer us a new therapeutic option against CKD and the aforementioned diseases as well.

**Acknowledgments**
This study was funded by the Turkish Hypertension and Kidney Diseases Association. This study was presented as a poster at the 53rd ERA-EDTA 2016 Congress under the name “SP370-Relationship between plasma YKL-40 levels and Endothelial dysfunction”.

145
References

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.

2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.

3. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta 2010; 411: 1412-1420.

4. Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, Townend JN. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012; 223: 86-94.

5. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.

6. Rehli M, Krause SW, Andreessen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 37: 221-225.

7. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-360.

8. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreessen R, Krause SW. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003; 278: 44058-44067.

9. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ. Strong induction of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. J Clin Oncol 2009; 27: 572-578.

10. Rathcke CN, Vestergaard H. YKL-40—an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009; 8: 61.

11. Johansen JS, Bojesen SE, Mylén AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009; 27: 572-578.

12. Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 96: 84-89.

13. Okyay GU, Er RE, Tekbudak MY, Paşaoğlu Ö, İnal S, Öncel K, Paşaoğlu H, Altok K, Derici Ü, Erten Y. Novel inflammatory marker in dialysis patients: YKL-40. Ther Apher Dial 2013; 17: 193-201.

14. Mygind ND, Iversen K, Kober L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V et al. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013; 273: 205-216.

15. Tatar E, Gungor O, Cektik A, Sisman AR, Yaprak M, Asci G, Ozkahya M, Toz H. Correlation between serum YKL-40 (chitinase-3-like protein 1) level and proteinuria in renal transplant recipients. Ann Transplant 2013; 18: 95-100.

16. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999; 180: 1722-1726.

17. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hoge Zand RA, de Vries RR, Breedveld FC, Boots AM. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-548.

18. Ghanavati S, Diep LM, Bárany P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Age Wallet S. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology 2014; 65: 443-449.

19. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhaker S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.

20. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kiliç S, Eyeleton T, Caglar K, Oguz Y, Vural A et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011; 26: 3537-3543.

21. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicuesu M, Covic A, Jalal D, Johnson RJ. Serum uric acid level and endothelial dysfunction in patients with non-diabetic chronic kidney disease. Am J Nephrol 2011; 33: 298-304.

22. Lee JH, Kim SS, Kim JI, Song SH, Kim YK, In Kim J, Jeon YK, Kim BH, Kwak IS. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J Diabetes Complications 2012; 26: 308-312.

23. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010; 26: 150-171.

24. Schernthaner GH, Höbaus C, Brix J. YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatol J Cardiol 2016; 16: 1286-1299.

25. Rusak A, Jabłońska K, Dzięgiel P. The role of YKL-40 in a cancerous process. Postepy Hig Med Dosw (Online) 2016; 70: 869.

26. Muszyński P, Grobiewska M, Kulczyńska-Przybik A, Kulakowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease. Curr Neuropharmaco 2017; 15: 906-917.

27. Jafari B, Mohsenin V. Chitinase-3-like protein-1 (YKL-40) as a marker of endothelial dysfunction in obstructive sleep apnea. Sleep Med 2016; 25: 87-92.